Loading company…
Molecular Insight Pharmaceuticals develops radiopharmaceuticals for the diagnosis and treatment of cancer.
Headquartered in Cambridge, US, Molecular Insight Pharmaceuticals develops novel radiopharmaceuticals for diagnosis and treatment in oncology. The company completed an IPO in February 2007, pricing 5 million shares at USD 5 each for USD 70 million in total. In 2009 it reported revenue of USD 5.50 million and EBITDA of USD -45.34 million. Its listed stage is Series C.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in